Valeant shares plunge nearly 30% after cutting its full-year forecast
November 08, 2016 at 06:19 AM EST
Valeant Pharmaceuticals reported an 11 percent fall in quarterly revenue due to faltering sales, and cut its full-year profit and revenue forecasts.
